Business Wire

BTS-GROUP

6.1.2020 15:37:14 CET | Business Wire | Press release

Share
BTS Acquires Rapid Learning Institute in the USA to Further Expand Its Portfolio of Digital Learning Offerings

BTS GROUP AB (publ), a leading global strategy implementation firm, has agreed to acquire the operations and all the assets of Rapid Learning Institute LLC based in Philadelphia (USA). Through its products and solutions Rapid Learning offers a differentiated approach to leadership and sales microlearning to clients in North America.

With the acquisition of Rapid Learning, BTS will gain a library of more than 200 proprietary learning modules centered on 5- to 7-minute research-backed videos, and in addition a collection of more than 2,500 articles on leadership and sales authored by the company’s editorial team. Rapid Learning’s Micro-First method to online training gives BTS thought leadership in single-concept learning facilitated by line leaders in the flow of work. The company will also bring a set of clients who subscribe to RLI’s programs or license its content. Its inside sales expertise and customer success management experience will help BTS increase its market penetration and expand its base of recurring revenue streams.

Rapid Learning was established in Philadelphia in 2008. Since then it has developed into a respected provider of leadership and sales micro-training to hundreds of clients. Its revenues over the last twelve months are approximately 2.8 MUSD. The company has 20 employees.

The executives of Rapid Learning, Stephen J. Meyer, Rob Krekstein and Michael Boyette, have agreed to stay on with BTS to drive the organization’s continued growth. An MBA graduate of the Wharton School at the University of Pennsylvania and founder of Rapid Learning, Meyer is an accomplished journalist, editor and publisher, having contributed to Forbes and Advertising Age and headed both editorial and marketing for more than two dozen employee development publications.

“We are delighted to welcome Rapid Learning to BTS,” says Henrik Ekelund, Founder & CEO of BTS. “This team creates impressive results for their clients through a comprehensive content library combined with a proven approach to leadership and sales learning in the flow of work. Together we will become an even stronger partner in the marketplace and accelerate our growth.”

“We are truly excited to become a part of the BTS family,” says Meyer, CEO of Rapid Learning. “We share the same approaches and points of view, which will make for an excellent fit. Being part of a global firm will also be a great opportunity for our customers and colleagues."

“And we believe our digital solutions and approach are a perfect complement to BTS’ current offerings,” adds Krekstein, Vice President of Sales for Rapid Learning.

“The addition of Rapid Learning to the BTS family strengthens substantially our digital content assets and thought leadership,” says Dave Ackley, Executive Vice President and Global Head of Digital at BTS. “The team brings us scalable digital solutions our clients expect and will support our efforts to build recurring license revenue.”

The acquisition includes an initial cash consideration. An additional payment will be paid out in 2023 provided the purchased operations meet specific targets 2020-2022.

BTS' strategy for acquisitions aims to create a broader base for future organic growth while actively consolidating in a highly fragmented market. Through its acquisitions, BTS also seeks to broaden its customer base and offering by bringing in new, existing and innovative services based on state-of-the-art digital technologies.

About BTS Group AB

BTS focuses on the people side of strategy, working with leaders at all levels to help them make better decisions, convert those decisions to actions and deliver results. At our core, we believe people learn best by doing. For over 30 years, we've been designing fun, powerful experiences that have a profound and lasting impact on people and their careers. We inspire new ways of thinking, build critical capabilities and unleash business success. It’s strategy made personal.

BTS is publicly traded on the Nasdaq Stockholm exchange under the symbol BTS B.

For more information, please visit www.bts.com .

Contact:

For more information, please contact: David Ackley Executive Vice President BTS Digital dave.ackley@bts.com +1.646.378.3535 Michael Wallin Head of investor relations BTS Group AB michael.wallin@bts.com +46-8-587 070 02 +46-708-78 80 19

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye